24 Sep Binocs
With 900 advanced therapies currently under investigation and 10 to 20 new therapy approvals each year from 2025 onwards, cell & gene therapy is going fast. This brings its own set of unique challenges. BINOCS is in pole position in ex-vivo CGT / advanced therapies in both commercial and clinical production. Currently, there are 4 commercial production CGT sites that already use BINOCS today and 6 leading CGT manufacturers that are evaluating BINOCS as their supply chain end-to-end planning solution.
•End- to- end integration with patient journey platforms (Trakcel, Vineti) and production shopfloor (LIMS, ERP).
•Automatic site & slot allocation, based on configurable assignment rules, optimizing utilization rates.
•Get visibility on what you project as available capacity in (slots/day) for patients’ batches.
•Automatic scheduling: Re-shuffle the schedule in real-time to deal with changes in the planning.
•End-to-end visibility: track progress & get real-time visibility across your different patient batches.